Загрузка...
ER-α36 mediates cisplatin resistance in breast cancer cells through EGFR/HER-2/ERK signaling pathway
BACKGROUND: ER-α36, a novel ER-α66 variant, has been demonstrated to promote tamoxifen resistance in breast cancer cells. However, the role and mechanisms of ER-α36 in cisplatin resistance of breast cancer cells remain unclear. This study investigates the expression and role of ER-α36 in cisplatin r...
Сохранить в:
| Опубликовано в: : | J Exp Clin Cancer Res |
|---|---|
| Главные авторы: | , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6019204/ https://ncbi.nlm.nih.gov/pubmed/29940998 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-018-0798-z |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|